ArticleProgress in neurobiology2026
Targeted interneuron ablation in an mTORopathy model: Testing a two-hit mechanism of epileptogenesis.
Article in Progress in neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Focal Cortical Dysplasia Type II: Somatic Mutations, Molecular Mechanisms, and Integrative Multi-Omics Framework.CNS neuroscience & therapeutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveSomatic mutations in mechanistic target of rapamycin (mTOR) pathway genes produce focal brain malformations that can lead to epilepsy. Malformations show a high degree of mosaicism, sometimes with less than 1% of neurons carrying the mutation. Seizures are hypothesized to be driven by mutation-carrying dysmorphic excitatory neurons, but lesions in patients and animal models also show loss of interneurons. Here, we queried whether interneuron loss could act as a second hit, releasing the brake on excitatory dysmorphic neurons and increasing epilepsy severity.
methodsTo test this hypothesis, we developed a two-hit mouse model in which we combined loss of the mTOR pathway inhibitor phosphatase and tensin homologue (Pten) from excitatory hippocampal dentate granule cells with ablation of local parvalbumin or somatostatin interneurons. Pten was deleted from roughly 3% of granule cells, a level which is subthreshold for producing frequent generalized seizures, thus facilitating assessment for synergistic effects.
resultsPten loss alone produced occasional seizures, while interneuron ablation alone initiated frequent seizures lasting for about one week, followed by a significant decline in seizure incidence in subsequent weeks. The combination of Pten deletion and interneuron ablation did not produce a synergistic increase in seizure incidence over ablation alone.
interpretationFindings confirm the potential for interneuron loss to drive epileptogenesis, but do not support the hypothesis that rapid disinhibition of Pten knockout granule cells enhances their ictogenic potential. Results provide new insights into the role of GABAergic inhibitory input in regulating the activity of mTOR hyperactive neurons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.